BRENTUXIMAB VEDONTIN FOR SKIN INVOLVEMENT IN REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL

被引：7
|
作者：
Fernandez-Codina, A. [1 ,2 ,3 ]
Nevskaya, T. [1 ]
Pope, J. [1 ]
机构：
[1] Western Univ, Div Rheumatol, Med, London, ON, Canada
[2] Windsor Reg Hosp Ouellette Campus, Med, Windsor, ON, Canada
[3] Hosp Clin Barcelona, Syst Autoimmune Dis, Barcelona, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0172
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [11] Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
    Spiera, Robert F.
    Gordon, Jessica K.
    Mersten, Jamie N.
    Magro, Cynthia M.
    Mehta, Mansi
    Wildman, Horatio F.
    Kloiber, Stacey
    Kirou, Kyriakos A.
    Lyman, Stephen
    Crow, Mary K.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1003 - 1009
  • [12] SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)
    Spiera, Robert
    Hummers, Laura
    Chung, Lorinda
    Frech, Tracy
    Domsic, Robin
    Hsu, Vivian
    Furst, Daniel
    Gordon, Jessica
    Mayes, Maureen
    Simms, Robert
    Lee, Elizabeth
    Constantine, Scott
    Dgetluck, Nancy
    White, Barbara
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 245 - 245
  • [13] A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
    Spierings, Julia
    van Rhenen, Anna
    Welsing, Paco M. W.
    Marijnissen, Anne C. A.
    De Langhe, Ellen
    Del Papa, Nicoletta
    Dierickx, Daan
    Gheorghe, Karina R.
    Henes, Joerg
    Hesselstrand, Roger
    Kerre, Tessa
    Ljungman, Per
    van de Loosdrecht, Arjan A.
    Marijt, Erik W. A. F.
    Mayer, Miro
    Schmalzing, Marc
    Schroers, Roland
    Smith, Vanessa
    Voll, Reinhard E.
    Vonk, Madelon C.
    Voskuyl, Alexandre E.
    de Vries-Bouwstra, Jeska K.
    Walker, Ulrich A.
    Wuttge, Dirk M.
    van Laar, Jacob M.
    BMJ OPEN, 2021, 11 (03):
  • [14] Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
    Chung, Lorinda
    Spino, Cathie
    McLain, Richard
    Johnson, Sindhu R.
    Denton, Christopher P.
    Molitor, Jerry A.
    Steen, Virginia D.
    Lafyatis, Robert
    Simms, Robert W.
    Kafaja, Suzanne
    Frech, Tracy M.
    Hsu, Vivien
    Domsic, Robyn T.
    Pope, Janet E.
    Gordon, Jessica K.
    Mayes, Maureen D.
    Sandorfi, Nora
    Hant, Faye N.
    Bernstein, Elana J.
    Chatterjee, Soumya
    Castelino, Flavia V.
    Ajam, Ali
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Whitfield, Michael L.
    Distler, Oliver
    Singer, Ora
    Young, Amber
    Nagaraja, Vivek
    Fox, David A.
    Furst, Daniel E.
    Khanna, Dinesh
    LANCET RHEUMATOLOGY, 2020, 2 (12): : E743 - E753
  • [15] Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
    Jessica K. Gordon
    Viktor Martyanov
    Cynthia Magro
    Horatio F. Wildman
    Tammara A. Wood
    Wei-Ti Huang
    Mary K. Crow
    Michael L. Whitfield
    Robert F. Spiera
    Arthritis Research & Therapy, 17
  • [16] Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
    Gordon, Jessica K.
    Martyanov, Viktor
    Magro, Cynthia
    Wildman, Horatio F.
    Wood, Tammara A.
    Huang, Wei-Ti
    Crow, Mary K.
    Whitfield, Michael L.
    Spiera, Robert F.
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [17] Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
    Spiera, Robert
    Hummers, Laura
    Chung, Lorinda
    Frech, Tracy
    Domsic, Robyn
    Hsu, Vivien
    Furst, Daniel
    Gordon, Jessica
    Myers, Madeline
    Simms, Robert W.
    Lee, Elizabeth
    Constantine, Scott
    Dgetluck, Nancy
    Bloom, Bradley
    White, Barbara
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [18] Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [19] Brentuximab vedotin compared with historical controls for severe skin involvement in cutaneous systemic sclerosis
    Fernandez-Codina, Andreu
    Nevskaya, Tatiana
    Baron, Murray
    Appleton, C. Thomas
    Cecchini, Matthew J.
    Philip, Amanda
    El-Shimy, Maha
    Vanderhoek, Louise
    Pinal-Fernandez, Iago
    Pope, Janet E.
    RHEUMATOLOGY, 2024,
  • [20] Treatment of sarcoidosis with cutaneous involvement with tofacitinib: Results of an open-label clinical trial with mechanistic insight
    Damsky, W.
    Wang, A.
    Young, B.
    Miller, E.
    King, B.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 22 - 22
12345